NORVIUM BIOSCIENCE Company Profile

✉ Email this page to a colleague

NORVIUM BIOSCIENCE has two hundred and forty-one approved drugs.

There are four US patents protecting NORVIUM BIOSCIENCE drugs. There is one tentative approval on NORVIUM BIOSCIENCE drugs.

There are fifty-one patent family members on NORVIUM BIOSCIENCE drugs in twenty-one countries and five hundred and thirty-three supplementary protection certificates in seventeen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	BUTISOL SODIUM	butabarbital sodium	TABLET;ORAL	000793-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	AMLODIPINE BESYLATE	amlodipine besylate	TABLET;ORAL	078224-001	Feb 27, 2008		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET;SUBLINGUAL	202657-001	Aug 8, 2016		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999	6,126,920	⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993	4,822,807	⤷ Sign Up
Norvium Bioscience	MIACALCIN	calcitonin salmon	SPRAY, METERED;NASAL	020313-002	Aug 17, 1995	5,733,569	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Foam	0.12%	➤ Subscribe	2007-08-10
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Inhalation Solution	0.021% and 0.042%	➤ Subscribe	2005-10-19
➤ Subscribe	Foam	2%	➤ Subscribe	2009-07-30
➤ Subscribe	Topical Foam	0.05%	➤ Subscribe	2005-06-27
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2006-12-13
➤ Subscribe	Nasal Spray	0.125 mg base/spray	➤ Subscribe	2005-11-14

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006024095	⤷ Sign Up
Canada	2578594	⤷ Sign Up
Spain	2429040	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1519731	13C0067	France	⤷ Sign Up	PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1663240	PA2015038	Lithuania	⤷ Sign Up	PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128
2498758	CR 2020 00017	Denmark	⤷ Sign Up	PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.